Prof Dr John N Giannios
DiplEngl(NYU),BSc(Biol)(USA),BSc(Chem)(USA),CertGCP(London),PGCertTMed(Edi
nburgh),PGDiplTMed(Edinburgh),MScTMed(Edinburgh),cMD(AM),PgCertFMed(Gl
asgow),cDSc (London),FRSM(London),MRSC(Cambridge) and M/D Prof (London)
in Translational Cancer Medicine.The three postgraduate degrees in Translational
Medicine were earned with Distinction from the Medical School of the University
of Edinburgh.He is the project leader of Translational Cancer Medicine in Medical
University Hospitals discovering as a cancer researcher novel
genomic/epigenomic personalised medicine therapeutic approaches,molecular
diagnostics based on pharmacogenomics and molecular oncology research
involving nanomedicine ,nanosurgery and oncogenomics/epigenomics .He is
discovering with Next Generation Sequencing in American Medical Universities
novel cancer related genes as targets for novel diagnostics and biological
treatments under a personalized cancer medicine approach based on
pharmacogenomics,pharmacoepigenomics and oncotheranostics. Furthermore,he
is a genomic counselor for preventive oncology involving hereditary
cancers,screening,diagnosis and oncotheranostics for personalized anticancer
treatment based on the tumour’s genomic and epigenomic profile.He is the
president and chief-editor of the Hellenic and International Society of Molecular
and Genomic Medicine and Research organizing three national oncology
congresses up to now with international participation.Furthermore,he is the
president of the International Association of the Personalised Perioperative
Medicine and Laser,Robotic and GENOMIC NANOSURGERY. Specifically,he has
invented many new anticancer treatments based on molecular oncology and
nanosurgery after adjuvant treatment facilitated by nanomedicine focusing on
nano-oncology and femto second laser leading to the eradication of cancer stem
cells with nanophotothermolysis.Also he has invented many stem cell therapies
for regenerative medicine which he has presented in American Congresses and in
Canada. He has organised as president of the scientific and organising committee
many molecular oncology congresses. He has approximately 3,000 CME credits
from the Medical School of Univ of Harvard,and other top American Medical
Universities such as John Hopkins,Univ of Alabama etc.He has certificates of
achievement for completing 144 credits in Category 1 of the Physicians
Recognition Award of the American Medical association and certificates of
medical courses covering all medical subspecialties of 50 credit hours each after
passing tests given by the American College of Physicians-American Society of
Internal Medicine.Also he has passed examinations for earning certificates with
medical credits from the American College of Surgeons where he has three years
of attendance in thoracic surgery where he perfected researchwise photodynamic
therapeutic approaches (PDT) facilitated by nanodelivery systems with molecular
targeting using antibodies against advanced lung cancers (NSCLC,SCLC,etc).For
this work he has been awarded from the Balkan School of Oncology and he has
presented them in plenary sessions of international Medical Laser Congresses.
Also he has attended breast surgeries for many years perfecting research
approaches of molecular surgery. He has been accredited by American Medical
Universities to lecture American Medical Doctors for meeting the continuing
medical education [CME] requirements required by American Medical Boards for
Recertification.He has been selected for inclusion in the Who is Who in Medicine ,
and he has been elected by the International Biographical Centre in Cambridge as
a top scientist in the arena of scientific research globally. He is an opinion leader
for the last two decades in genomic and epigenomic cancer medicine where he
has written three books and approximately 5,000 lectures,posters and
publications in International Oncology Congresses and Journals with more than
500 awards in novel treatments based on personalized cancer medicine and
translational medicine including oncology, cardiology, regenerative
medicine,endocrinology, gynaecology,neurology and other medical subspecialties
where omic technology and nanomedicine might be applied mainly for tailoring
individualized treatments to cancer patients with incurable solid tumors such as
glioblastoma multiforme and metastatic tumors applying molecular targeting
approaches for circumvention of chemo/radio/immune-resistant mechanisms
using antisense treatments for downregulating antiapoptotic oncogenes and gene
therapy or epigenetic therapy for re-expression of silenced apoptotic tumor
suppressor genes.Induction of D2 irreversible stage of apoptosis is monitored by
electron microscopy where he has a great expertise from the University of
London.Prof John Giannios has contributed as genomic counselor to the national
genomic guidelines for breast cancer screening,diagnosis and treatment.He has
teaching experience in many governmental(public) and private oncology hospitals
where he has been directing cancer research with genomic approaches focusing
on personalized cancer medicine.Finally,he is the founding and active
member/fellow of many medical societies such as the International Society of
Gastrointestinal Oncology (ISGIO),European Society of Gynaecological Oncology
(ESGO),American Society of Clinical Oncology (ASCO),American Association of
Cancer Research (AACR),International Academy of Legal Medicine
(IALM),European Society of Human Genetics (ESHG), National Society of Genetic
Counselors (NSGC) etc.He is qualified to teach and practice translationally all
personalized medicine therapeutic approaches where as a Translational Medicine
practicioner he can take these novel treatments from bench to clinic.